Trials / Withdrawn
WithdrawnNCT02691780
Study to Evaluate the Safety and Efficacy of Sorafenib, in Subject With Refractory Solid Tumors
- Status
- Withdrawn
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Samsung Medical Center · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This study is a single arm, pilot study of Sorafenib in patient with BRAF mutation Refractory solid tumor and specific sensitivity to Sorafenib by Avatar scan that has progressed following standard therapy or that has not responded to standard therapy or for which there is no standard therapy. To investigate the efficacy and safety of Sorafenib in patient with Refractory solid tumor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sorafenib |
Timeline
- Start date
- 2016-12-23
- Primary completion
- 2018-12-01
- Completion
- 2019-11-19
- First posted
- 2016-02-25
- Last updated
- 2019-12-30
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02691780. Inclusion in this directory is not an endorsement.